Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
نویسندگان
چکیده
منابع مشابه
Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
BACKGROUND Pemphigus is a severe autoimmune blistering disorder caused by autoantibodies to desmoglein 1 and 3. The disease course is typically severe, thus requiring multiple immunosuppressive agents. The treatment is still challenging and in some patients with recalcitrant disease, therapies fail and therapeutic options are limited. OBJECTIVES To investigate whether depletion of B lymphocyt...
متن کاملOfatumumab: a novel monoclonal anti-CD20 antibody
Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC). Pha...
متن کاملTreatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
BACKGROUND Rituximab, a chimeric monoclonal anti-CD20 antibody, has recently been used for the treatment of refractory antibody mediated autoimmune diseases such as immune mediated thrombocytopenia and haemolytic anaemia. PATIENTS Because of its novel mechanism of action, rituximab was used to treat three patients with refractory systemic antibody mediated autoimmune disorders. The first pati...
متن کاملproduction and characterization of new anti-human cd20 monoclonal antibody
the b-cell cd20 antigen is one of the most reliable surface targets in immunotherapy of b lymphoma. in this project, we studied the production and characterization of a new monoclonal antibody against chimeric human cd20 extra loops (hcd20 exl). the results showed that clone c12h, igg2/k isotype reacted with the antigen in elisa and immunoblot. the kd value was found to be 2×10-9m and flow cyt...
متن کاملRituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders.
Haematologica/journal of hematology vol. 88(02):February 2003 223 post-splenectomy was 3.5±4.3% which is higher than the values in normal subjects (below 2%) and much lower than those found in SCD patients after total splenectomy (more than 20%). These results imply significant preservation of splenic function in our patients. No recurrence of ASS occurred after the operation. Admissions to hos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2014
ISSN: 0887-6924,1476-5551
DOI: 10.1038/leu.2014.146